Through our relentless dedication, we have emerged as frontrunners in the fields of oncology, hematology, transplant cases, and rare diseases. Since 2004, we have proudly partnered with over 15 international companies and extended our reach to several other Latin American nations.
Our primary focus is on developing and manufacturing high-quality pharmaceuticals, driven by an unwavering commitment to optimizing patient care. Our distinguished reputation stems from long-standing collaborations with the medical and scientific communities, where we prioritize innovation and continuous improvement in line with rigorous international quality standards.
registered
products worldwide
products in
Latin America
Another year of expanding our scientific expertise in this academic event.
In Varifarma we continue to take part in scientific events to stay at the forefront of new healthcare innovations.
Find the latest news of this innovative test as a genomic tool to evaluate tumour behavior over the years for an accurate choice of treatment.
Present at the “Daily Hematology” Conference in Montevideo from April 24 to 26.
Our genomic test myChoice CDx Plus has been recognized by the ESGO-ESMO-ESP 2024 consensus with a Level of Evidence 1A.
Varifarma launched GORAX® (Relugolix) at the International Symposium “Advances in Urology 2024” organized by the Argentine Society of Urology.
We Launched Gorax (Relugolix) 120mg, the first LHRH antagonist with oral intake in Argentina.
Developed by Varifarma, Gorax is a revolutionary breakthrough in advanced prostate cancer treatment.
A new therapeutic alternative with multiple indications arrives to Varifarma!
